Pulmonary Large Cell Neuroendocrine Carcinoma Clinical Trial
Official title:
Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma: a Prospective, Randomized, Open-label, Phase 2 Study
The primary endpoint is to compare the PFS (progress-free survival ) of etoposide plus carboplatin with paclitaxel combined with carboplatin as first-line treatment for advanced pulmonary large cell neuroendocrine carcinoma.
The primary endpoint is to compare the PFS (progress-free survival ) of etoposide plus
carboplatin with paclitaxel combined with carboplatin as first-line treatment for advanced
pulmonary large cell neuroendocrine carcinoma.
In addition, gene spectrum detection and Mini-PDX are applied for validation of
pharmacodynamic.
Results of clinical trials and pharmacodynamic test will be analyzed to provide evidence for
the precise treatment for LCNEC.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment